Cannabis-associated arteritis

Vasa - Journal of Vascular Diseases

Volumn 39, Issue 1, 2010, Pages 43-53

  Grotenhermen, Franjo ^a  

^a Nova Institut   (Germany)

Author keywords

Buerger's disease; Cannabis arteritis; Dronabinal; Marijuana; Thromboangiitis obliterans

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL;

ARTERITIS; BUERGER DISEASE; CANNABIS ADDICTION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CASE STUDY; CIGARETTE SMOKING; CLINICAL FEATURE; HUMAN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TOBACCO;

ARTERITIS; CANNABIS; HUMANS; MARIJUANA ABUSE; THROMBOANGIITIS OBLITERANS;

EID: 77749273851     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000004     Document Type: Review

References (85)

1. Adams MD, Earnhardt JT, Dewey WL, Harris LS. Vasoconstrictor actions of delta8-and delta9-tetrahydrocannabinol in the rat. J Pharmacol Exp Ther 1976; 196 (3): 649-56.
2. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58 (4): 315-48.
3. Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis 2006 271: 14.
4. Ates A, Yekeler I, Ceviz M, Erkut B, Pac M, Basoglu A, Kocak H. One of the most frequent vascular diseases in northeastern of Turkey: Thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol 2006; 111 (1): 147-53.
5. Beaconsfield P, Ginsburg J, Rainsbury R: Marihuana smoking: cardiovascular effects in man and possible mechanisms. N Engl J Med 1972; 287: 209-12.
6. Benowitz NL, Rosenberg J, Rogers W, Bachman J, Jones RT. Cardiovascular effects of intravenous Delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther 1979; 25: 440-6.
7. Bozkurt AK, Beşirli K, Köksal C, Sirin G, Yüceyar L, Tüzün H, Sayin AG. Surgical treatment of Buerger's disease. Vascular 2004; 12 (3): 192-7.
8. Buerger L. Thrombangiitis obliterans: a study of the vascular lesions leading to prensile spontaneous gangrene. Am J Med Sci 1908; 136: 567-80.
9. Cazalets C, Laurat E, Cador B, Jan F, Rolland Y, Jego P, Grosbois B. Artériopathies du cannabis: quatre nouveaux cas. Rev Med Interne 2003; 24 (2): 127-30.
10. Coetzee C, Levendal RA, van de Venter M, Frost CL. Anticoagulant effects of a Cannabis extract in an obese rat model. Phytomedicine 2007; 14 (5): 333-7.
11. Combemale P, Consort T, Denis-Thelis L, Estival JL, Dupin M, Kanitakis J. Cannabis arteritis. Br J Dermatol 2005; 152 (1): 166-9.
12. Constans J, Dubiez P, Baste JC, Barcat D, Parrot F, Conri C. Artériopathie du cannabis. Presse Med 1999; 28 (39): 2154.
13. Dehaine-Bamberger N, Amar R, Touboul C, Emmerich J, Fiessinger JN. Maladie de Buer ger: Aspects cliniques et prognostiques; 83 observations. Presse Med 1993; 22 (20): 945-8.
14. Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 2004; 99 (4): 1127-30.
15. Disdier P, Granel B, Serratrice J, Constans J, Michon-Pasturel U, Hachulla E, Conri C, Devulder B, Swiader L, Piquet P, Branchereau A, Jouglard J, Moulin G, Weiller PJ. Cannabis arteritis revisited - ten new case reports. Angiology 2001; 52 (1): 1-5.
16. Disdier P, Swiader L, Jouglard J, Piquet P, Christides C, Moulin G, Harle JR, Weiller PJ. Artérite du cannabis versus maladie de Leo Buerger. Discussion nosologique à propos de deux nouveaux cas. Presse Med 1999; 28 (2): 71-4.
17. Ducasse E, Chevalier J, Dasnoy D, Speziale F, Fiorani P, Puppinck P. Popliteal artery entrapment associated with cannabis arteritis. Eur J Vasc Endovasc Surg 2004; 27 (3): 327-32.
18. Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007; 130 (Pt 12): 3091-101.
19. Eichhorn J, Sima D, Lindschau C, Turowski A, Schmidt H, Schneider W, Haller H, Luft FC. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 1998; 315 (1): 17-23.
20. Fredericks AB, Benowitz NL, Savanapridi CY. The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. J Pharmacol Exp Ther 1981; 216 (2): 247-53.
21. Gardiner SM, March JE, Kemp PA, Bennett T. Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 2002; 135 (8): 1889-96.
22. Gash A, Karliner JS, Janowsky D, Lake CR. Effects of smoking marihuana on left ventricular performance and plasma norepinephrine: studies in normal men. Ann Intern Med 1978; 89: 448-52.
23. Glueck CJ, Haque M, Winarska M, Dharashivkar S, Fontaine RN, Zhu B, Wang P. Stromelysin-1 5A / 6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease. Clin Appl Thromb Hemost 2006; 12 (4): 427-39.
24. Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Huestis MA. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 2006; 151 (3): 754. e1-754.e5.
25. Gröger A, Aslani A, Wolter T, Noah EM, Pallua N. Ein seltener Fall von Cannabis-Arteritis. Vasa 2003; 32 (2): 95-7.
26. Halpern M, Citron BP. Necrotizing angiitis associated with drug abuse. Am J Roentgenol Radium Ther Nucl Med 1971; 111 (4): 663-71.
27. Heper G, Kose S, Akkoc O, Amasyali B, Kilic A. Two female nonsmoker Buerger's disease cases with anticardiolipin autoantibodies and a poor prognosis. Int Heart J 2005; 46 (3): 563-9.
28. Herning RI, Better WE, Tate K, Cadet JL. Cerebrovascular perfusion in marijuana users during a month of monitored abstinence. Neurology 2005; 64 (3): 488-93.
29. Herning RI, Better WE, Tate K, Cadet JL. Marijuana abusers are at increased risk for stroke. Preliminary evidence from cerebrovascular perfusion data. Ann N Y Acad Sci 2001; 939: 413-5.
30. Hirai M, Shionoya S. Arterial obstruction of the upper limb in Buerger's disease: its incidence and primary lesion. Br J Surg 1979; 66 (2): 124-8.
31. Ho WS, Hiley CR. Endothelium-independent relaxation to cannabinoids in rat-isolated mesenteric artery and role of Ca2+ influx. Br J Pharmacol 2003; 139 (3): 585-97.
32. Hoeft D, Kroger K, Grabbe S, Dissemond J. Thromboangiitis obliterans: Eine Übersicht J Dtsch Dermatol Ges 2004; 2 (10): 827-32.
33. Högestätt ED, Zygmunt PM. Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 2002; 66 (2-3): 343-51.
34. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of Delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: effects on ventilatory control and cardiovascular dynamics. Anesthesiology 1975; 42: 674-84.
35. Jones RT, Benowitz NL, Herning RI: Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21: 143S-152S.
36. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002;42(11 Suppl): 58S-63S.
37. Kanakis C Jr, Pouget JM, Rosen KM. The effects of Delta- 9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation 1976; 53: 703-7.
38. Kanakis C, Pouget M, Rosen KM. Lack of cardiovascular effects of Delta-9-tetrahydrocannabinol in chemically denervated men. Ann Intern Med 1979;91:571-4.
39. Karila L, Danel T, Coscas S, Chambon JP, Reynaud M. L'artérite progressive cannabique, un sous-type clinique de la thromboangéite oblitérante? Presse Med 2004; 33 (18 Suppl): 21-3.
40. Kjeldsen K, Mozes M. Buerger's disease in Israel. Investigations on carboxyhemoglobin and serum cholesterol levels after smoking. Acta Chir Scand 1969; 135 (6): 495-8.
41. Launay D, Queyrel V, Hatron PY, Michon-Pasturel U, Hachulla E, Devulder B. Nécroses digitales chez une patiente ayant une anorexie mentale. Presse Med 2000; 29: 1850-2.
42. Lazarides MK, Georgiadis GS, Papas TT, Nikolopoulos ES. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds 2006; 5 (2): 89-95.
43. Le Berre R, Lhomme E, Queyrel V, Pasturel U, Hachulla E, Hatron PY, Devulder B, Chambon JP. Les arterites juveniles: le cannabis, un nouveau acteur de risque. Rev Med Interne 1999; 20 (Suppl 1): 136.
44. Leithäuser B, Langheinrich AC, Rau WS, Tillmanns H, Matthias FR. A 22-year-old woman with lower limb arteriopathy. Buerger's disease, or methamphetamine-or cannabis-induced arteritis? Heart Vessels 2005; 20 (1): 39-43.
45. Lie JT. Thromboangiitis obliterans (Buerger's disease) in an elderly man after cessation of cigarette smoking - a case report. Angiology 1987; 38 (11): 864-7.
46. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346 Pt 3: 835-40.
47. López-Miranda V, Herradón E, Martín MI. Vasorelaxation caused by cannabinoids: mechanisms in different vascular beds. Curr Vasc Pharmacol 2008; 6 (4): 335-46.
48. Makita S, Nakamura M, Murakami H, Komoda K, Kawazoe K, Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 1996; 94 (9 Suppl): II211-5.
49. McDougall JJ, Yu V, Thomson J. In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. Br J Pharmacol 2008; 153 (2): 358-66.
50. Mendizábal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 2007; 151 (4): 427-40.
51. Mills JL Sr. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg 2003; 16 (3): 179-89.
52. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103 (23): 2805-9.
53. Mouzak A, Agathos P, Kerezoudi E, Mantas A, Vourdeli-Yiannakoura E: Transient ischemic attack in heavy cannabis smokers - how 'safe' is it? Eur Neurol 2000; 44: 42-44.
54. Nahas GG. Cannabis arteritis. N Engl J Med 1971;284(2):113.
55. Noël B, Ruf I, Panizzon RG. Cannabis arteritis. J Am Acad Dermatol. 2008 May; 58 (5 Suppl 1): S65-7.
56. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006; 18 (1): 18-24.
57. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990; 82 (5 Suppl): IV 3-8.
58. Olin JW. Thrombangiitis Obliterans. In: Creager MA, Dzau VJ, Loscalzo J (Hrsg.). Vascular Medicine, a Companion to Braunwald's Heart Disease. Philadelphia: Saunders Elsevier 2006: 641-656.
59. O'Sullivan SE, Kendall DA, Randall MD. The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 2005b; 145 (4): 514-26.
60. Pacher P, Bátkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol. 2005; (168): 599-625.
61. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58 (3): 389-462.
62. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008; 52 (4): 601-7.
63. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 1996; 11 (3): 335-9.
64. Peyrot I, Garsaud AM, Saint-Cyr I, Quitman O, Sanchez B, Quist D. Cannabis arteritis: a new case report and a review of the literature. J Eur Acad Dermatol Venereol 2007; 21 (3): 388-91.
65. Pillard RC. Letter to the editor. N Engl J Med 1971;284(2):113.
66. Pillard RC. Marihuana. N Engl J Med 1970; 283 (6): 294-303.
67. Plange N, Arend KO, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A, Huth J, Sponsel WE, Remky A. Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 2007; 143 (1): 173-4.
68. Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology (Oxford) 2007; 46 (2): 192-9.
69. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293: H2210-2218.
70. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 2008; 153: 347-57.
71. Ralevic V, Kendall DA. Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mes enteric arteries. Eur J Pharmacol 2002; 444 (3): 171-81.
72. Randall MD, Kendall DA, O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004; 142 (1): 20-6.
73. Romano MR, Lograno MD. Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol 2006; 147 (8): 917-25.
74. Sauvanier M, Constans J, Skopinski S, Barcat D, Berard A, Parrot F, Guerin V, Vergnes C, Midy D, Baste JC, Conri C. Les artériopathies des membres inférieurs débutant avant 50 ans. J Mal Vasc 2002; 27 (2): 69-76.
75. Schneider F, Abdoucheli-Baudot N, Tassart M, Boudghene F, Gouny P. Cannabis et tabac : co-facteurs favorisant l'artériopathie oblitérante juvénile. J Mal Vasc 2000; 25 (5): 388-9.
76. Schneider HJ, Jha S, Burnand KG. Progressive arteritis associated with cannabis use. Eur J Vasc Endovasc Surg 1999; 18 (4): 366-7.
77. Seinturier C, Pichot O, Blaise S, Imbert B, Carpentier P. Ischémie subaiguë d'un membre inférieur et toxicité artérielle périphérique de la cocaïne chez une patiente présentant une artériopathie juvénile. J Mal Vasc 2006; 31 (2): 76-8.
78. Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998; 66 Suppl 1: S243-5.
79. Shmist YA, Goncharov I, Eichler M, Shneyvays V, Isaac A, Vogel Z, Shainberg A. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 2006; 283 (1-2): 75-83.
80. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434 (7034): 782-6.
81. Stein EA, Fuller SA, Edgemond WS, Campbell WB. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol 1996; 119 (1): 107-14.
82. Sterne J, Ducastaing C. Les artérites du cannabis indica. Arch Mal Coeur 1960; 53: 143-7.
83. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998; 243 (3): 838-43.
84. White D, Martin D, Geller T, Pittman T. Stroke associated with marijuana abuse. Pediatr Neurosurg 2000; 32 (2): 92-4.
85. Winiwarter F. Über eine eigentümliche Form von Endarteriitis und Endophlebitis mit Gangrän des Fusses. Arch Klein Chir 1878; 23: 202-26.